Guggenheim 3rd Annual Healthcare Innovation Conference - COHERUS ONCOLOGY INC

Explicit Guidance:

• Sales Targets: Management aims to increase Lactorsi (lactucide) annual sales from the current $14–$15 million range to $25–$35 million to cover core burn expenses.
• Runway/Break-even: Targeting to achieve core burn break-even (overhead excluding clinical trial costs) within the next four to five quarters (approx. 2026) by reducing quarterly core burn from a prior $30–$35 million to $25–$30 million.
• Cost Savings: Restructuring and headcount reduction (30% cut) yielding immediate quarterly savings of $6–$7 million with lasting duration.
• Divestiture/Debt: Completed divestiture of biosimilar business generating $800 million in proceeds; paid off $500 million in debt and retained $250 million on the balance sheet (referenced as completed to support future cash flow).

Business-Segment Outlook:

• Prioritized Indication (Esophageal): Strategic focus shifted exclusively to first-line and second-line esophageal cancer (squamous and adenocarcinoma histologies). Second-line is the initial priority for accelerated development due to unmet need and potential for fast-track approval.
• De-prioritized Indications: Esophageal (first line) will follow second-line success; other indications (head and neck, gastric, colorectal, CRC) are currently non-prioritized for internal development but will be pursued via partnerships or combinations.
• Pipeline Expansion: Initiating a new clinical study for TAGMO-Ketog combined with Pazritamab (J&J's KLK2 TCE) in prostate cancer to validate safety and microenvironment remodeling.
• Commercial Strategy (Lactorsi): Aggressively targeting market share growth in nasopharyngeal indications by converting "chemo-only" patients (via payer data review) and overcoming "off-label IO" barriers by implementing step-edit restrictions with payers.

Market and Competitive Outlook:

• Target Population: Esophageal cancer represents the sixth leading cause of cancer deaths globally, with >400,000 patients annually ex-US, specifically in Asia.
• Competitive Benchmarking: TAGMO-Ketog data shows an 89% ORR in 1L esophageal squamous (vs. standard of care ~44–60%) and 33–44% ORR in 2L setting (vs. chemo-only ~10%). Management views this as a potential threefold increase over chemotherapy benchmarks, supporting accelerated approval pathways.
• Pricing/Reimbursement: Securing step- edits with payers to restrict off-label IO use has successfully increased Lactorsi market share in targeted payer contracts to ~60% (from low 20s).
• Partnership Activity: Actively seeking partnering funds to offset clinical costs for TAGMO-Ketog, leveraging the strong esophageal data signal to attract collaborators for global development.

Macro / Industry Outlook:

• Regulatory Timing: Scheduled FDA Type B meeting in early 2027 to align on Recommended Phase 2 Dose (RP2D) and discuss a randomized Phase 2 study design for second-line approval, aiming for Accelerated/ Fast Track/ Breakthrough designations.
• Global Market Dynamics: Emphasis on ex-US markets (particularly Asia) for the esophageal indication due to high patient volume and unmet need.
• Clinical Landscape: Belief that reversing PD-1 resistance and activating "cold" tumors (PD-L1 low/negative) via Treg depletion creates a structural advantage for combination therapies, including ADCs and T-cell engagers.

Strategic Initiatives:

• Organizational Right-Sizing: Implementing a 30% headcount reduction (primarily non-commercial) to reduce overhead and accelerate the path to self-sufficiency.
• Regulatory Alignment: Filing FDA meeting requests in early 2027 to secure dosing and development plan alignment for the esophageal program.
• M&A/Partnership Strategy: Hiring a financial advisor to facilitate licensing/partnership deals for TAGMO-Ketog in the US and ex-US markets to share development costs.
• Asset Transfer: Completed transfer of Toropalimab (PD-1) from China to US, eliminating associated overhead and burn.

Risks and Headwinds to Outlook:

• Clinical Trial Success: The entire roadmap to break-even and profitability hinges on the success of the Phase 2 registrational study in second-line esophageal cancer; failure to demonstrate superiority over chemotherapy (10% ORR benchmark) or secure FDA agreement on endpoints would derail the timeline.
• Timeline Uncertainty: FDA alignment on dosing and study design (randomized vs. seamless) is pending; any delay in the early 2027 meeting could push back the second-line study initiation.
• Commercial Execution: Market penetration for Lactorsi currently lags (20–22% share vs. 40% off-label IO); failure to convert patients from chemo-only or off-label IO segments could delay break-even beyond the four-quarter target.
• Combination Safety: The upcoming Pazritamab + TAGMO-Ketog study in prostate cancer carries risk; while safety is the primary metric, toxicity could limit future T-cell engager combinations.
• Market Share Pressure: Significant competition from established IO/chemo regimens in esophageal cancer requires rapid demonstration of survival benefit (6-month median survival in 2L) to gain adoption.

Management Tone on the Future:

• Confidence: High confidence in the clinical signal, describing the data as "very encouraging," "strong," and "exciting," with a focus on "streamlined development."
• Strategic Pivot: Tone is decisive and focused on "right-sizing" the organization to achieve "self-sufficiency" sooner rather than later.
• Urgency: Management expresses frustration with the current slow pace of Lactorsi adoption ("need to go faster") and emphasizes immediate action to close the gap between current sales ($14–$15M) and break-even targets ($25–$35M).
• Optimism on Partnerships: Belief that the esophageal data strength removes barriers to securing partners and funding, contrasting with previous difficulties in discussing development in less active tumor types.